Approximately 50% of women with epithelial ovarian cancer have homologous recombination deficient (HRD) tumours.1,2 Identification can aid prognosis and inform treatment decisions.3-7

Find out more about why, when and how to test here.

Approximately 50% of women with epithelial ovarian cancer have homologous recombination deficient (HRD) tumours.1,2 Identification can aid prognosis and inform treatment decisions.3-7

Find out more about why, when and how to test here.

Molecular Landscape of Ovarian Cancer and the Importance of HRD Testing Importance

What is an HRD Test? About

How is an HRD Test Performed? Process

Understand HRD Test Results Interpretation

Familial Risk and Genetic Counselling Genetic Counselling

1. Konstantinopoulos PA, et al. Cancer Discov 2015;5:1137–1154; 2. Bonadio RRCC, et al. Clinics (Sao Paulo) 2018;73(suppl.1):e450s; 3. Audeh MW, et al. Lancet 2010;376:245–251; 4. Ledermann J, et al. Lancet Oncol 2014;15:852–861; 5. Ray-Coquard I, et al. Presented at European Society for Medical Oncology Annual Meeting 2019; 27th September – 1st October 2019; Barcelona, Spain; 6. Abkevich V, et al. Br J Cancer 2012;107:1776–1782; 7. González-Martin A, et al. N Engl J Med 2019;381:2391–2402

Back to top